Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Leukemia|May 26, 2018
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug responseKana Sakamoto, Ryohei Katayama, Reimi Asaka, et al.
International Journal of Hematology|June 10, 2010
Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantationTatsuo Furukawa, Tori Kurasaki-Ida, Masayoshi Masuko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2012
Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal typeYoshinori Ito, Hiroshi Kimura, Yoshinobu Maeda, et al.
Cancer Medicine|January 18, 2024
Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patientsYasumasa Shimasaki, Hiroaki Miyoshi, Keisuke Kawamoto, et al.
Cancer Science|May 4, 2021
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphomaYasuhito Terui, Shinya Rai, Koji Izutsu, et al.
Internal Medicine (Tokyo, Japan)|March 18, 2014
Early diagnosis of hepatic intravascular lymphoma: a case report and literature reviewHiroyuki Abe, Kenya Kamimura, Maiko Mamizu, et al.
Haematologica|September 14, 2014
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in JapanTomohiro Aoki, Koji Izutsu, Ritsuro Suzuki, et al.
Hematological Oncology|September 26, 2020
Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphomaKatsuhiro Miura, Hideki Tsujimura, Yasufumi Masaki, et al.
Leukemia & Lymphoma|June 21, 2016
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphomaNaoto Tomita, Taisei Suzuki, Kazuho Miyashita, et al.
Annals of Hematology|April 20, 2019
Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal originMotoko Yamaguchi, Ritsuro Suzuki, Kana Miyazaki, et al.
Pageof 8